NoraWho am I? Why are you here? Are we compatible?I start from this premise: I write here because I have an infinite amount of time on my hands, and writing is perhaps the only activity…Mar 3
Ranjani Ramamurthyinllmed.aiPediatric AML: Starting with the scienceThanks to Dr. Soheil Meshinchi MD, PhD and Julie A. Guillot for their input and for sharing content for this article. Much gratitude for…Sep 6, 2022
Drew DotsonGrief Gab: How I got hereI became a widow July 20, 2020. Here’s the short version of how it happened.May 26, 20221May 26, 20221
Dr. SHIVA Ayyadurai, MIT PhDDr.SHIVA BROADCAST: Molecular Systems Architecture of Acute Myeloid Leukemia (AML).In this discussion, Dr. Shiva Ayyadurai shares the findings of CytoSolve’s recent results in mapping out the molecular systems architecture…Apr 18, 2022Apr 18, 2022
The Leukemia & Lymphoma SocietyFDA Approval of New Treatment Option for Children with Secondary Acute Myeloid Leukemia is a…By Gwen Nichols, MD, LLS Chief Medical Officer | March, 2021Apr 4, 2021Apr 4, 2021
NoraWho am I? Why are you here? Are we compatible?I start from this premise: I write here because I have an infinite amount of time on my hands, and writing is perhaps the only activity…Mar 3
Ranjani Ramamurthyinllmed.aiPediatric AML: Starting with the scienceThanks to Dr. Soheil Meshinchi MD, PhD and Julie A. Guillot for their input and for sharing content for this article. Much gratitude for…Sep 6, 2022
Drew DotsonGrief Gab: How I got hereI became a widow July 20, 2020. Here’s the short version of how it happened.May 26, 20221
Dr. SHIVA Ayyadurai, MIT PhDDr.SHIVA BROADCAST: Molecular Systems Architecture of Acute Myeloid Leukemia (AML).In this discussion, Dr. Shiva Ayyadurai shares the findings of CytoSolve’s recent results in mapping out the molecular systems architecture…Apr 18, 2022
The Leukemia & Lymphoma SocietyFDA Approval of New Treatment Option for Children with Secondary Acute Myeloid Leukemia is a…By Gwen Nichols, MD, LLS Chief Medical Officer | March, 2021Apr 4, 2021
HKUMedinHKU MedicinePersonalising Treatment for One of the Most Lethal Cancers“For the 60–70% patients who do not respond well to conventional chemotherapy, we hope by understanding their unique genetic underpinnings…Sep 28, 2020
The Leukemia & Lymphoma SocietyBeat AML in the Time of COVID-19: A Powerful New VideoLike many clinical trials across the U.S. and the globe, The Leukemia & Lymphoma’s Beat AML Master Trial has been dramatically impacted by…May 15, 2020
Mission BioMD Anderson Analyzes AML With Tapestri, Unveiling New Therapy Response PatternsBy Charlie Silver, Co-Founder & CEO, Mission BioApr 20, 2020
